BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reiffel JA. Time in the Therapeutic Range for Patients Taking Warfarin in Clinical Trials: Useful, but Also Misleading, Misused, and Overinterpreted.Circulation. 2017;135:1475-1477. [PMID: 28416519 DOI: 10.1161/CIRCULATIONAHA.116.026854] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Singh M. Would Less Anticoagulation Be Acceptable in Less-Developed Regions? Glob Heart 2018;13:245-6. [PMID: 30509550 DOI: 10.1016/j.gheart.2018.09.510] [Reference Citation Analysis]
2 Lin Y, Xiong H, Su J, Lin J, Zhou Q, Lin M, Zhao W, Peng F. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation. Heart Vessels 2022. [PMID: 35041061 DOI: 10.1007/s00380-022-02021-2] [Reference Citation Analysis]
3 Shields LBE, Fowler P, Siemens DM, Lorenz DJ, Wilson KC, Hester ST, Honaker JT. Standardized warfarin monitoring decreases adverse drug reactions.BMC Fam Pract. 2019;20:151. [PMID: 31699045 DOI: 10.1186/s12875-019-1041-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Kamuren Z, Kigen G, Keter A, Maritim A. Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings. BMC Health Serv Res 2018;18:723. [PMID: 30231891 DOI: 10.1186/s12913-018-3537-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]
6 Guimarães PO, Lopes RD, Alexander JH, Thomas L, Hellkamp AS, Hijazi Z, Hylek EM, Gersh BJ, Garcia DA, Verheugt FWA, Hanna M, Flaker G, Vinereanu D, Granger CB. International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. J Thromb Thrombolysis 2019;48:27-34. [PMID: 30972712 DOI: 10.1007/s11239-019-01858-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Neumann I, Izcovich A, Aguilar R, Basantes GL, Casais P, Colorio CC, Esposito MCG, Lázaro PPG, Meillon-García LA, Pereira J, Rezende SM, Serrano JC, Valle MLT, Vera F, Karzulovic L, Rada G, Schünemann H. ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America. Blood Adv 2021;5:3032-46. [PMID: 34374748 DOI: 10.1182/bloodadvances.2021004267] [Reference Citation Analysis]
8 Krittayaphong R, Chantrarat T, Rojjarekampai R, Jittham P, Sairat P, Lip GYH. Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry. J Clin Med 2020;9:E1698. [PMID: 32498302 DOI: 10.3390/jcm9061698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Neumann I, Schünemann HJ, Bero L, Cooke G, Magrini N, Moja L. Global access to affordable direct oral anticoagulants. Bull World Health Organ 2021;99:653-60. [PMID: 34475602 DOI: 10.2471/BLT.20.278473] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Durães AR, de Souza Lima Bitar Y, Filho JAL, Schonhofen IS, Camara EJN, Roever L, Cardoso HEDP, Akrami KM. Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study. Drugs R D 2018;18:303-8. [PMID: 30293126 DOI: 10.1007/s40268-018-0249-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Duraes AR, de Souza Lima Bitar Y, Schonhofen IS, Travassos KSO, Pereira LV, Filho JAL, Neto MG, Junior RA, Roever L. Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial-The RIWA study. Am J Cardiovasc Drugs 2021;21:363-71. [PMID: 33150497 DOI: 10.1007/s40256-020-00449-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Botto GL, Ameri P, De Caterina R. Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. J Clin Med 2021;10:2866. [PMID: 34203416 DOI: 10.3390/jcm10132866] [Reference Citation Analysis]
13 Siddiqui S, DeRemer CE, Waller JL, Gujral JS. Variability in the Calculation of Time in Therapeutic Range for the Quality Control Measurement of Warfarin. J Innov Card Rhythm Manag 2018;9:3428-34. [PMID: 32494479 DOI: 10.19102/icrm.2018.091203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Gallinoro E, D'Elia S, Prozzo D, Lioncino M, Natale F, Golino P, Cimmino G. Cognitive Function and Atrial Fibrillation: From the Strength of Relationship to the Dark Side of Prevention. Is There a Contribution from Sinus Rhythm Restoration and Maintenance? Medicina (Kaunas) 2019;55:E587. [PMID: 31540311 DOI: 10.3390/medicina55090587] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
15 Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Troy K, Schiano T, Mascarenhas J. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv 2020;4:655-66. [PMID: 32078681 DOI: 10.1182/bloodadvances.2019001310] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
16 Yan CH, Naveed M, Alobaidi A, Kopfman M, Nutescu EA, Sharp LK, Cannegieter DS. Association between transportation barriers and anticoagulation control among an inner-city, low-income population: A prospective observational cohort study. Res Pract Thromb Haemost 2021;5:e12605. [PMID: 34755020 DOI: 10.1002/rth2.12605] [Reference Citation Analysis]
17 Reiffel JA. TTR: Time in Therapeutic Range or "The Troublesome Report"? J Innov Card Rhythm Manag 2019;10:3469-70. [PMID: 32477700 DOI: 10.19102/icrm.2019.100103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]